Point72 Asset Management
ASND icon

Point72 Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Point72 Asset Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-20,000
Closed -$1.78M – 2450
2023
Q2 		$1.78M Buy
+20,000
New +$1.74M 0.01% 1060
2022
Q3 		– Sell
-35,000
Closed -$3.25M – 1397
2022
Q2 		$3.25M Buy
+35,000
New +$3.3M 0.01% 813

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management's ASND Position: Q2 2025 in Review

Point72 Asset Management sold out of Ascendis Pharma A/S (ASND) in Q2 2025, closing a stake of 569,146 shares — an estimated $88.7M sold.

Point72 Asset Management first reported a position in ASND in Q1 2020 and held it in 12 quarters. The position peaked at $88.7M in Q1 2025. 247 funds tracked by Wall St. Rank hold ASND as of Q2 2025.

  • Point72 Asset Management reported no remaining Ascendis Pharma A/S position as of Q2 2025 after selling out during the quarter.
  • Point72 Asset Management sold 569,146 Ascendis Pharma A/S shares in Q2 2025, an estimated $88.7M.
  • Point72 Asset Management first reported a position in Ascendis Pharma A/S in Q1 2020 and held it in 12 quarters.
  • Point72 Asset Management's Ascendis Pharma A/S position peaked at $88.7M in Q1 2025.
  • 247 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2025.

Based on Point72 Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.